NEW YORK, Sept 19, 2016 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, today announced it will disclose new mechanistic data on the activity of its NAP technology in HBV and HDV infection at the 2016 International Meeting of the Molecular Biology of Hepatitis B Viruses, to be held from Sept 21-24, 2016 in Seoul, Korea (http://www.hepb.org/research-and-programs/international-hbv-meeting/).
Studies ongoing with viral hepatitis experts in France at the Institute Nationale de la Transfusion Sanguine in Paris and the Centre de Recherche en Cancerologie de Lyon have been examining the antiviral effects of NAPs in cellular models of HBV and HDV infection. Results of these studies will be disclosed in two separate poster presentations to be presented on Thursday, September 22 and will focus on the ability of different NAPs (including the clinically active NAPs REP 2055 and REP 2139 ) to block the entry of these viruses into cells.
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com.